JPWO2020047352A5 - - Google Patents

Info

Publication number

JPWO2020047352A5

JPWO2020047352A5 JP2021510984A JP2021510984A JPWO2020047352A5 JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5 JP 2021510984 A JP2021510984 A JP 2021510984A JP 2021510984 A JP2021510984 A JP 2021510984A JP WO2020047352 A5 JPWO2020047352 A5 JP WO2020047352A5

Authority

JP

Japan

Prior art keywords

hae

composition

antibody

treatment period

prior

Prior art date

2022-09-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 claims 27
• 206010019860 Hereditary angioedema Diseases 0.000 claims 26
• 239000000203 mixture Substances 0.000 claims 23
• 238000000034 method Methods 0.000 claims 7
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
• 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 3
• 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims 3
• 239000003098 androgen Substances 0.000 claims 2
• 229940009550 c1 esterase inhibitor Drugs 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
• 229920000053 polysorbate 80 Polymers 0.000 claims 2
• 229940068968 polysorbate 80 Drugs 0.000 claims 2
• 239000011780 sodium chloride Substances 0.000 claims 2
• 239000001488 sodium phosphate Substances 0.000 claims 2
• 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 229940122155 Bradykinin receptor antagonist Drugs 0.000 claims 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
• 229940030486 androgens Drugs 0.000 claims 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
• 239000000504 antifibrinolytic agent Substances 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 239000003152 bradykinin antagonist Substances 0.000 claims 1
• POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims 1
• 229960000766 danazol Drugs 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 229960001174 ecallantide Drugs 0.000 claims 1
• 108010011867 ecallantide Proteins 0.000 claims 1
• 239000000262 estrogen Substances 0.000 claims 1
• 229940011871 estrogen Drugs 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 claims 1
• 108700023918 icatibant Proteins 0.000 claims 1
• 229960001062 icatibant Drugs 0.000 claims 1
• VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 claims 1
• 230000007774 longterm Effects 0.000 claims 1
• 238000002483 medication Methods 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 229940126155 plasma kallikrein inhibitor Drugs 0.000 claims 1
• 238000011321 prophylaxis Methods 0.000 claims 1
• GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims 1
• 229960000401 tranexamic acid Drugs 0.000 claims 1